Cogent Biosciences Inc

COGT is in Stage 3 distribution after a decisive support failure and Bearish Pivot Point, establishing a bearish medium-term bias. Price trades below declining EMAs and rejects rallies into the 9/20 EMA region, justifying immediate sell-side engagement. Extreme oversold conditions introduce risk of a relief bounce, but the downtrend remains intact until key support breaks.

• ↑Phase 3 PEAK trial showed 50% lower progression risk.
• ↑Three NDAs pending; two under FDA priority review late 2026.
• ↓Q2 ’26 net loss $96.4M (+31.7% YoY); profitability remains negative.